Sartorius AG hits €3.5B in 2025 sales amid biopharma expansion and leadership moves
Sartorius AG has reported strong financial performance, with sales reaching around €3.5 billion in 2025. The company, a key supplier to biopharmaceutical research and manufacturing, operates through two main divisions: Lab Products & Services and Bioprocess Solutions. Recent leadership updates and strategic acquisitions have further solidified its market position. The company has expanded significantly through acquisitions since 2015. In 2016, it entered the bioanalytics sector with US-based purchases. More recently, Sartorius completed a billion-euro deal for French firm Polyplus, boosting its capabilities in cell and gene therapies.
Dr. René Fabér, who oversees the Bioprocess Solutions Division, has had his Executive Board membership extended until December 31, 2031. He joined Sartorius in 2002 as a scientist before rising through management roles. A polymer chemistry Ph.D. from the Technical University of Munich, he has played a key role in the division's growth. Sartorius employs over 14,000 people across roughly 60 global production and sales sites. Investors and analysts can expect financial updates on April 23, 2026 (Q1), July 23, 2026 (half-year), and October 22, 2026 (nine-month results).
With a global workforce and a strong acquisition strategy, Sartorius AG continues to strengthen its position in biopharmaceutical support. The extension of Dr. Fabér's leadership term and upcoming financial reports will likely shape the company's next phase of growth. Key dates for financial disclosures have been set for 2026.
